Now, more than ever, the field of cardiology needs women. 

This is 4MD’s cardiac nuclear imaging analysis software, shown here integrated with a ScImage cardiovascular information system (CVIS). Both companies displayed on the expo floor at ASNC 2019. The software creates a single page report seen here. PET perfusion imaging was a big topics at the conference. #ASNC #ASNC19 #ASNC2019

There were a few key takeaways from the American Society of Nuclear Cardiology (ASNC) 2019 annual meeting in September, these included...
The three sites most often used for distal radial artery access are the (1) anatomic snuffbox above the scaphoid (left), (2) adjacent to the snuffbox at the trapezium bone (center), and (3) the first intermetacarpal space (right). The author’s preference is either of the first two options, although good outcomes have been reported with use of the intermetacarpal space.

Interest in distal radial artery access (DRA) is growing rapidly. Among the benefits of DRA are the low risk of entry site bleeding complications and the low rate of radial artery occlusion.[1,2] This is an overview of the benefits of using distal radial vascular access in the area of the anatomical snuff box in the cath lab. 
 

Faster Hemostasis With Distal Radial Access

November 21, 2019 — At the American Heart Association Scientific Sessions 2019, Eko, a digital health company applying artificial intelligence (AI) and machine learning in the fight against heart disease, presented results in collaboration with

November 21, 2019 — People who experience cardiac arrests over the weekend are less likely to survive long enough to be admitted to a hospital, compared to those who had the same medical event on a weekday, according to preliminary research to be presented at the American Heart Association’s Resuscitation Science Symposium 2019 — November 16-17 in Philadelphia. 

November 21, 2019 — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), presented positive first-in-human data of the Cordella Pulmonary Artery (PA) Pressure Sensor System. Data was presented at the 2019 American Heart Association (AHA) scientific sessions by Prof. Dr. Wilfried Mullens of the Hospital Oost-Limburg in Genk, Belgium.

Associate Director, Resynchronization and Advanced Cardiac Therapeutics Program
Massachusetts General Hospital 

It’s an exciting time in the heart failure (HF) world right now with the emergence of new therapies, including medications and devices. Several of these were highlighted in sessions at the 2019 American Heart Association (AHA) scientific sessions.

November 21, 2019 — Merck announced the results from the Phase 3 VICTORIA Study evaluating the efficacy and safety of vericiguat, met the primary efficacy endpoint for reducing the risk of heart failure hospitalization and cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF). The new drug outperformed patients given a placebo in combination with available heart failure therapies. 

November 20, 2019 — Heart attack survivors may have an increased risk of developing cancer compared to people without cardiovascular disease, according to research presented at the American Heart Association’s Scientific Sessions 2019 — Nov. 16-18 in Philadelphia. The Association’s Scientific Sessions is an annual, premier global exchange of the latest advances in cardiovascular science for researchers and clinicians.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now